Abstracts tagged "gout"

Abstract Number: 2278 • 2016 ACR/ARHP Annual Meeting
Precision of Gout Definitions for Population-Based Genetic Studies: Analysis of the UK Biobank
Murray Cadzow¹, Tony R. Merriman² and Nicola Dalbeth³, ¹University of Otago, Dunedin, New Zealand, ²Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ³University of Auckland, Auckland, New Zealand
Background/Purpose : Accurate case-definition is important for epidemiological studies of gout. However, in multipurpose cohort studies frequently used for genome wide association studies, limited information…
Abstract Number: 3139 • 2016 ACR/ARHP Annual Meeting
Breaking the Cycle: Analyzing Preventable Hospital Admissions Due to Gout
Pieusha Malhotra¹, Nikky Keer² and Robert Yood³, ¹Internal Medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ²Internal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA, ³Department of rheumatology and musculoskeletal medicine, Department of Medicine, Division of Rheumatic Diseases and Musculoskeletal Medicine, Saint Vincent Hospital, Worcester, MA
Background/Purpose: Despite available effective treatment options and published guidelines for gout management, many patients suffer from recurrent gout attacks. Increases in gout prevalence and continued…
Abstract Number: 190 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Michael Gillen¹, Zangong Shen² and Jeffrey N. Miner³, ¹AstraZeneca, Gaithersburg, MD, ²Ardea Biosciences, San Diego, CA, ³Discovery Biology, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study. Panels of 8 male subjects (6 active, 2 placebo) received a…
Abstract Number: 219 • 2016 ACR/ARHP Annual Meeting
Presence of Monosodium Urate Crystals By Dual-Energy Computed Tomography in Gout Patients Treated with Allopurinol
Nicola Dalbeth¹, Savvas Nicolaou², Scott Baumgartner³, Jia Hu³, Maple Fung³ and Hyon K. Choi⁴, ¹University of Auckland, Auckland, New Zealand, ²Radiology, University of British Columbia, Vancouver, BC, Canada, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic hyperuricemia predisposes to deposition of monosodium urate (MSU) crystals in musculoskeletal and other tissues, causing chronic inflammation, acute gout flares, joint damage, and…
Abstract Number: 2280 • 2016 ACR/ARHP Annual Meeting
Monosodium Urate Crystal-Induced Inflammation Promotes Osteocyte Expression of Pro-Resorptive and Inflammatory Mediators: Implications for Erosive Gout
Ashika Chhana¹, Mei-Lin Tay², Bregina Pool³, Karen E. Callon², David Musson², Dorit Naot¹, Gregory Gamble³, Jillian Cornish³ and Nicola Dalbeth², ¹Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Bone erosion in gout is strongly associated with tophi; lesions comprising of inflammatory cells surrounding collections of monosodium urate (MSU) crystals. Osteocytes are…
Abstract Number: 3199 • 2016 ACR/ARHP Annual Meeting
Urate Crystal Deposition and Bone Erosion in Gout: Inside-out or Outside-in? a Dual Energy Computed Tomography Study
Patapong Towiwat¹, Anthony Doyle¹, Gregory Gamble², Paul Tan¹, Opetaia Aati², Anne Horne², Lisa K. Stamp³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: Imaging and pathology studies have shown that bone erosion is closely associated with monosodium urate (MSU) crystal deposition in tophaceous gout. It is currently…
Abstract Number: 191 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects
James VanderLugt¹, Michael Gillen², Xiaojuan Yang³ and Jesse Hall³, ¹Jasper Clinical Research & Development, Kalamazoo, MI, ²AstraZeneca, Gaithersburg, MD, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1,…
Abstract Number: 220 • 2016 ACR/ARHP Annual Meeting
Urate Lowering Therapy Regresses Ultrasound Abnormalities in Gout
Siddharth K. Das¹, Harikrishnan Velayudhan², Danveer Bhadu³, Urmila Dhakad⁴ and Ragini Srivastava⁵, ¹Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ²Rheumatology, Senior Resident, Rheumatology, K.G. Medical University, Lucknow, India, Luknow, India, ³Rheumatology, Senior Resident III, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁴Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India, ⁵Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India
Background/Purpose: Detection of double contour sign (DCS) and hyperechoic aggregates (HAG) is a reliable method in detecting urate crystal deposition by ultrasound (US) which has…
Abstract Number: 2283 • 2016 ACR/ARHP Annual Meeting
Suppression of Monosodium Urate (MSU) Crystals-Induced Inflammatory Response By Inhibiting TGF-β Activated Kinase 1 (TAK1)
Anil Singh¹, Kayla O’Sullivan², Mukesh Chourasia³, Sadiq Umar⁴, Mahamudul Haque², Bhanupriya Madarampalli² and Salahuddin Ahmed², ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: Methods: Results: Conclusion:
Abstract Number: 192 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic and Pharmacokinetic Study of Verinurad in Adult Male Subjects with Mild, Moderate, and Severe Renal Impairment: A Phase 1, Open-Label Study
William B Smith¹, Jesse Hall², Jolene Berg³, Michal Kazimir⁴, Amy Yamamoto², Caroline Lee², Susan Walker² and Thomas C. Marbury⁵, ¹Volunteer Research Group, Knoxville, TN, ²Ardea Biosciences, Inc., San Diego, CA, ³DaVita Clinical Research, Minneapolis, MN, ⁴DaVita Clinical Research, Lakewood, CO, ⁵Orlando Clinical Research Center, Orlando, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 1, single-dose, open-label study…
Abstract Number: 223 • 2016 ACR/ARHP Annual Meeting
Clinical Predictors of Acute Gout Flares within Hospitalized Patients at a Tertiary Care Center in New York
Lara El Khoury¹, Mohamad Yasmin^1,2, Nabil Zeineddine¹, Joseph Saabiye¹, Saleha Riaz¹, Sami Arnaout¹, Talal El Imad¹, Suzanne El-Sayegh³ and Rita Obeid⁴, ¹Internal Medicine, Staten Island University Hospital, Northwell Health, Staten Island, NY, ²Infectious Diseases, Case Western Reserve University, Cleveland, OH, ³Internal Medicine, Program Director, Staten Island University Hospital, Northwell Health, Staten Island, NY, ⁴Psychology, The Graduate Center, CUNY, New York, NY
Background/Purpose: Gout is the most prevalent inflammatory arthritis worldwide. Within the healthcare setting, gout flares contribute to substantial morbidity and complicated hospital stays. Identifying risk…
Abstract Number: 2284 • 2016 ACR/ARHP Annual Meeting
Differential Effect of MSU-Crystal Induced Inflammation on Macrophage Polarization
Rashid Ahmed¹, Nicole Yang², Changqi Sun³ and Anthony M. Reginato³, ¹Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, MA, USA., Boston, MA, ³Division of Rheumatology, Rhode Island Hosital/The Warren Alpert School of Medicine of Brown University, Providence, RI
Background/Purpose: Gouty arthritis is a common inflammatory joint disease that arises in response to the deposition of monosodium urate (MSU) crystals in soft joints, periarticular…
Abstract Number: 240 • 2015 ACR/ARHP Annual Meeting
Volumetric Assessment of Tophaceous Gout
Ralf G. Thiele¹, Laura Coates² and Darren Tabechian¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine, University of Rochester, Rochester, NY
Background/Purpose: Ultrasound (US) can identify monosodium urate (MSU) tophi within joints, tendons, bursae and other soft tissues. The ability to readily, quickly and inexpensively assess…
Abstract Number: 2241 • 2015 ACR/ARHP Annual Meeting
Treating to Target in Gout: The Epidemiology of Serum Urate Measurement Among Patients with Incident Gout in Usual Care Settings in the United States
Marsha Raebel¹, Liza Reifler¹, David Tabano¹, Kristin Goddard¹, Andrew Sterrett¹, T Craig Cheetham², Leslie Harrold³, Daniel Sapp⁴, Mark Schmidt⁴, Javier Nuevo⁵, Robert Morlock⁶ and Gregory Nichols⁴, ¹Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, ²Kaiser Permanente Southern California, Pasadena, CA, ³Dept of Medicine, UMass Medical School, Worcester, MA, ⁴Center for Health Research, Kaiser Permanente Northwest, Portland, OR, ⁵AstraZeneca, Madrid, Spain, Madrid, Spain, ⁶Ardea Bioscience, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend lowering serum urate (sUA) to a target value in patients with gout to prevent crystal deposition/promote crystal…
Abstract Number: 241 • 2015 ACR/ARHP Annual Meeting
Inflammatory Syndrome in Polyarticular Gout – Description of a Previously Neglected Entity
Valentin S. Schäfer¹, Andreas Krause² and Wolfgang A. Schmidt², ¹Immanuel Krankenhaus Berlin, Medical Center for Rheumatology Berlin-Buch, Berlin, Germany, ²Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany
Background/Purpose: Inflammatory polyarticular gout occurs in clinical practice. However, only very few single case reports have been published as yet. This case series aims at…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].